See the DrugPatentWatch profile for Zepbound
What prescription market share does Zepbound have?
Zepbound (tirzepatide) is a prescription-only medicine, but the provided information does not include any figures for its prescription market share (for example, share by prescriptions, by sales, or by patients). Without an explicit market-share source, it isn’t possible to state a number accurately.
Where can you find reliable Zepbound prescription market-share numbers?
To get a defensible “prescription market share” figure, look for tracking from specialty pharmacy analytics, prescription audit data providers, or insurer/market research releases that break out:
- Share by number of prescriptions written
- Share by prescription volume (not just revenue)
- Share within GLP-1/GIP agonists or within obesity pharmacotherapy
DrugPatentWatch.com is useful for patent/exclusivity context around brand products, but it typically isn’t a primary source for prescription market-share metrics. If you want, share the timeframe (e.g., 2024 YTD, latest 12 weeks) and the geographic scope (US vs. specific country/state), and I can help pinpoint the right kind of market-share source to use.
Is Zepbound’s share usually reported vs. Ozempic/Wegovy/Mounjaro?
Yes, market-share reporting in this drug class is commonly benchmarked against other incretin therapies (including Ozempic and Wegovy, and for diabetes indications, Mounjaro). If your goal is a “Zepbound vs. competitors” view, you’ll usually find:
- Market share within obesity indications only, or
- Share within all GLP-1/GIP prescriptions combined
What timeframe and definition changes the market-share number?
The “market share” can shift a lot depending on whether the report uses:
- Month vs. quarter vs. rolling 12 weeks
- Script counts vs. net sales
- Obesity indication only vs. diabetes plus obesity
- New prescriptions only vs. total prescriptions (including refills)
If you tell me which definition you mean (script count or sales, and which indication set), I can structure the answer around that specific interpretation.
If you meant “how much of the obesity market is Zepbound,” what should you check?
For obesity-focused market share, confirm the denominator used in the study:
- All anti-obesity prescriptions (including older agents), or
- Only modern incretin-based anti-obesity drugs
That choice can change the apparent share substantially.
If you paste a link, screenshot, or the exact wording of the report you’re looking at, I can extract the precise Zepbound market-share figure and restate it clearly.
Sources
No sources were provided in the prompt that contain Zepbound prescription market-share data.